Compare DexCom, Inc. (DXCM) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Remitly Global Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while Remitly Global Inc trades at $23.5 (market cap $4.85B). The key difference: DexCom, Inc. is far larger — about 6.6× Remitly Global Inc's market cap, and DexCom, Inc. is more actively traded (2,861,821 versus 2,599,081). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Remitly Global Inc for 53 Days on average.
| DXCM | RELY | |
|---|---|---|
Market Cap | $31.81B | $4.85B |
Volume | 2,861,821 | 2,599,081 |
Sector | Health | Technology |
52-Week High | $92.34 | $26.92 |
52-Week Low | $54.84 | $12.20 |
Typical Hold Time | 62 Days | 53 Days |
Enterprise Value | $31.26B | $4.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
RELY trades at $23.52, up 1.38% today, with a bullish technical signal from moving averages. The company shows strong fundamental momentum, with revenue growing from $654M in 2022 to $1.64B in 2025 and turning profitable with a net income of $67.93M. Recent Q2 2026 earnings beat expectations with EPS of $0.93 versus $0.12 expected, and active customers surpassed 10 million. Positive cash flow trends and a partnership with Etsy highlight operational strength and growth initiatives.
The outlook for RELY is positive, supported by accelerating revenue growth, expanding profit margins, and strong analyst consensus with a $30.50 price target. Key risks include reliance on continued customer expansion, competitive pressures in digital payments, and market volatility. The stock presents an opportunity for growth investors given its earnings beats and bullish institutional sentiment, though execution on growth targets remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
